Personal Skills, Job Satisfaction, And Productivity In Members Of High Performance Teams

The intention of the study is to identify the development of personal skills, as well as the increase of job satisfaction and productivity of the employee, as a result of their participation in high performance teams. Volunteered in the study 139 members of self-managed teams belonging to the Production Area, 39 of Operational Administrative teams, 19 members of Cross-Functional teams and 6 of 6-Sigma Projects, all of them belonging to a company of the Maquiladora Industry in Tijuana, B.C., Mico. The study indicates that 100% of the members of the Production Area teams and the Operational Administrative teams developed some personal skills or increased their satisfaction or productivity as a result of their participation in some kind of self-managed team. In Cross-Functional teams members, the changes took place in the 94.3% of the cases and in the 97% of the 6-Sigma teams members. There was also a significant difference found between the results of the four types of self-managed teams studied. This paper provides information to CEOs regarding the importance of the design and the implementation of working programs for self-managed teams; these not only will strengthen the employee achievement of a greater satisfaction and productivity, but will also allow them to develop personal skills

Jerarquizacion de productos en una empresa de aserrio

54 p.La memoria aborda un estudio de los productos generados por una empresa de aserrado de mediana capacidad ubicada en la Séptima Región del Maule. Se calculo la contribución individual a la utilidad, lo que permitió jerarquizar según su aporte a la utilidad total de la empresa. El estudio pretende contribuir a la toma de decisiones en la empresa, con la finalidad de elevar Las utilidades mediante la selección de los productos de mejor rendimiento y, por lo tanto, haciéndola mas competitiva frente a empresas similares. Los resultados permitieron identificar el orden de los productos de acuerdo a su aporte a la utilidad total de la empresa y mostraron una Clara diferencia entre ellos, dependiendo principalmente del sector de la troza de donde se extraen

Riesgo dietético para la presencia de dislipidemias en escolares

La asociación del consumo de alimentos con la presencia de enfermedades crónicas , en particular con las enfermedades cardiovasculares en niños es limitada . Los factores de riesgo cardiovascular como las dislipidemias, han sido descritos recientemente a edades cada vez más tempranas en los que los niños en edad escolar no han sido la excepción. La dieta de baja calidad es un factor de riesgo que debe ser intervenido y modificado en la población, sobre todo en edades tempranas.Objetivo: Identificar el riesgo dietético por el consumo de alimentos con elevado contenido de azúcares refinados, ácidos grasos saturados y colesterol para la presencia de dislipidemias en escolares. Materiales y métodos: Se diseñó y aplicó una encuesta de frecuencia de consumo de alimentos de riesgo, se calculó el riesgo dietético y se identificaron alteraciones lipídicas en niños. Se utilizó la razón de momios con intervalos de confianza al 95% para la medición del riesgo entre la dieta y las dislipidemias. Resultados: 17% de los escolares de la escuela privada presentaron consumo elevado de colesterol; en la escuela pública 59% presentaron elevado consumo de azúcares refinados, y 29% consumo elevado de ácidos grasos saturados. Las cifras de riesgo de colesterol sérico, triglicéridos y colesterol-LDL se identificaron con mayor frecuencia en los escolares de la institución privada, mientras que las cifras bajas de colesterol-HDL se identificaron con mayor frecuencia en los niños de la escuela pública. 64 escolares con riesgo dietético presentaron al menos un tipo de dislipidemia OR= 0.94; IC 95%, 0.59-1.50. Conclusiones: En ésta población, el consumo elevado de azúcares refinados es el factor de riesgo dietético de mayor frecuencia para la presencia de dislipidemias. La dieta de baja calidad es un factor de riesgo que debe ser modificado en la población, sobre todo en edades temprana

Can the pyruvate: ferredoxin oxidoreductase (PFOR) gene be used as an additional marker to discriminate among Blastocystis strains or subtypes?

Background Blastocystis spp. are the most prevalent intestinal eukaryotes identified in humans, with at least 17 genetic subtypes (ST) based on genes coding for the small-subunit ribosomal RNA (18S). It has been argued that the 18S gene should not be the marker of choice to discriminate between STs of these strains because this marker exhibits high intra-genomic polymorphism. By contrast, pyruvate:ferredoxin oxidoreductase (PFOR) is a relevant enzyme involved in the core energy metabolism of many anaerobic microorganisms such as Blastocystis, which, in other protozoa, shows more polymorphisms than the 18S gene and thus may offer finer discrimination when trying to identify Blastocystis ST. Therefore, the objective of the present study was to assess the suitability of the PFOR gene as an additional marker to discriminate among Blastocystis strains or subtypes from symptomatic carrier children. Methods Faecal samples from 192 children with gastrointestinal symptoms from the State of Mexico were submitted for coprological study. Twenty-one of these samples were positive only for Blastocystis spp.; these samples were analysed by PCR sequencing of regions of the 18S and PFOR genes. The amplicons were purified and sequenced; afterwards, both markers were assessed for genetic diversity. Results The 18S analysis showed the following frequencies of Blastocystis subtypes: ST3 = 43%; ST1 = 38%; ST2 = 14%; and ST7 = 5%. Additionally, using subtype-specific primer sets, two samples showed mixed Blastocystis ST1 and ST2 infection. For PFOR, Bayesian inference revealed the presence of three clades (I-III); two of them grouped different ST samples, and one grouped six samples of ST3 (III). Nucleotide diversity (π) and haplotype polymorphism (θ) for the 18S analysis were similar for ST1 and ST2 (π = ~0.025 and θ = ~0.036); remarkably, ST3 showed almost 10-fold lower values. For PFOR, a similar trend was found: clade I and II had π = ~0.05 and θ = ~0.05, whereas for clade III, the values were almost 6-fold lower. Conclusions Although the fragment of the PFOR gene analysed in the present study did not allow discrimination between Blastocystis STs, this marker grouped the samples in three clades with strengthened support, suggesting that PFOR may be under different selective pressures and evolutionary histories than the 18S gene. Interestingly, the ST3 sequences showed lower variability with probable purifying selection in both markers, meaning that evolutionary forces drive differential processes among Blastocystis STs

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years